Project Details
Description
Protocol M23-716: A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata Protocol Date:01 June 2023
| Status | Active |
|---|---|
| Effective start/end date | 9/29/23 → 9/30/33 |
Funding
- ABBVIE INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.